Original Research

Association of Deslorelin and Sulpiride for Double Ovulation Induction in Mares

Ariel Bertoldi, Lorenzo Garrido Segabinazzi, Camila de Paula Freitas Dell’Aqua, Jose Antonio Dell’Aqua Junior, Marco Antonio Alvarenga

Article info

Article history:
Received 19 June 2018
Received in revised form 18 July 2018
Accepted 18 July 2018
Available online 21 August 2018

Keywords:
Equine
GnRH
superovulation
antidopaminergic
dopamine

Abstract

The aim of this study was to verify the effect of deslorelin and sulpiride association on double ovulation induction in mares. Ten mares were used for this study. Eight days after ovulation, luteolysis was induced and mares were submitted a daily ultrasonographic evaluation until observation of at least two follicles measuring between 20 and 25 mm. Animals were split in two experimental groups in a crossover study. In deslorelin (DES) group, the animals received 150 mg deslorelin, intramuscularly, every 12 hours, until the second largest follicle reached at least 33 mm in diameter, at which time ovulation induction was performed with 1,500 IU of human chorionic gonadotrophin, IV. In the DES + sulpiride (SULP) group, the treatment was performed in the same manner as in the DES group, associated with the administration of 1 g of sulpiride, orally, once daily until the time of ovulations induction. In both groups, ultrasound examinations were performed daily to evaluate follicular development and the detection of ovulations. Double ovulations were observed in 70% (7/10) of the animals of the DES group and 50% (5/10) of the animals in the DES + SULP group. The percentage of ovulations corresponding to the number of follicles developed was 81.8% (18/22) for the DES group and 79% (15/19) for the DES + SULP group, and no difference was observed between the groups (P > .05). We conclude that association of sulpiride with deslorelin acetate did not contribute to the increase in double ovulations in mares.

1. Introduction

To improve reproductive efficiency in mares, an alternative is to increase the number of ovulations per cycle, which would lead to an increase in embryo recovery rates, consequently reducing the costs involved in embryo transfer programs [1]. Treatments to induce multiple ovulations in mares have been described by several authors, however, followed by reduced embryo recovery rates because they decrease with the great number of ovulations [2–6], due to the fact related to the formation of a large clot in the ovulation fossa, which impairs the transport of oocytes to the oviduct after ovulation [6]. Thus, embryo recovery rates may be high if the number of ovulation per ovary is limited to two or three [6].

Among the hormones used for this purpose, equine pituitary extract and purified equine follicle stimulating hormone are the most studied drugs. However, the difficulty of acquisition, added with the high cost and inconstant results of these hormonal preparations, limit the diffusion of superovulation in the equine species [7]. The use of low-cost, high-availability, synthetic hormone such as deslorelin acetate has been studied to induce double ovulation in mares, with multiple ovulation rates being observed in about 70% of mares submitted to treatment [7–11].

Sulpiride promotes the production of prolactin that acts directly on follicle stimulating hormone (FSH) and luteinizing hormone...
(LH) receptors of the follicles [12]. Studies reported the efficiency of sulpiride in hastening cyclicity in mares in anestrus [13] and in transition phase [14]. Considering that inhibit, a hormone FSH suppressor, is secreted by the dominant follicle causing atresia of the other follicles, but this one still growing by the relative FSH independence, due to the higher amount of FSH and LH receptors in granulosa cells [15], sulpiride appears as a possible strategy to improve receptor expression in the second largest follicle, improving follicles’ capacity to grow until preovulatory size, raising the percentage of mares that respond to the treatment of double ovulation induction. In this context, the aim of the present study was to verify the effect of sulpiride and deslorelin association for double ovulation induction in mares.

2. Material and Methods

This study was approved by the Animal Care and Use Committee of São Paulo State University with protocol number 0177/2017.

2.1. Animals

Ten crossbreed mares, with ages ranging from 3 to 20 years and weighing between 350 and 450 kg, from the Equine Breeding Center—CER, located in Boituva City/SP were used. The animals were maintained in paddocks formed by coast-cross grass (Cynodon dactylon), with free access to water and mineral salt, receiving 4 kg of commercial ration for equines, twice a day.

2.2. Ultrasonographic Control

Ultrasound evaluation was performed daily using a 5 MHz linear transducer (Mindray DP2200Vet, Shenzhen, China) to identify follicular development and ovulation. The follicular diameter was obtained considering the average of the two linear measurements of the antrum taken at right angles.

2.3. Experimental Groups

The experiment was performed between January and March of 2017. Four cycles of each animal were used. The first cycle with the objective of evaluating follicular development and ovulation served as pretreatment control. Animals that had double spontaneous ovulations and ovulation failures were not used in this study. The last cycle was followed to verify possible changes in the follicular dynamics as a function of the treatments performed, without pharmacological manipulation. Between the pretreatment and posttreatment control cycles, two cycles of each animal were used for the experiment. Eight days after ovulation, ultrasonographic examination was performed to confirm the presence of corpus luteum and to evaluate the follicular population in the ovaries. At this time, 5 mg of dinoprostone tromethamine (Lutalyse, Pfizer, New York, USA) were injected intramuscularly (IM) to perform lutetasis, and ultrasonographic examinations were performed daily. When at least two follicles between 20 and 25 mm were observed, the animals were randomly assigned to one of the two treatment groups (DES [deslorelin] group or DES + SULP [sulpiride] group). In the subsequent cycle, the mares were changed in groups, following the cross-over model. Ovulation inductions were performed when the second largest follicle reached at least 33 mm or the largest follicle ≥38 mm, and grade 2 uterine edema [16] with 1500 IU of human chorionic gonadotrophin (hCG—Vetecor Laboratório Calier, São Paulo, Brazil), intravenously. In the DES group, 150 micrograms (μg) of deslorelin acetate (Sincorrelin, Ouro Fino, Brazil) was administered IM, every 12 hours, until ovulation induction. Ultrasonographic examinations continued until ovulation was observed. In the DES + SULP group, deslorelin acetate applications were performed as described previously, concomitantly with the administration of 1 g of sulpiride (Drogavet—Veterinary Handling Pharmacy—Curitiba, Paraná, Brazil) orally, every 24 hours, until the time of ovulation induction. In animals that follicular growth was not observed after 3 days of treatment, it was interrupted to avoid downregulation, as observed in a recent study [7], and the animal was evaluated until a corpus luteum (CL) is diagnosed and the next cycle was used.

2.4. Statistical Analysis

Statistical analyses were performed using GraphPad Prism version 6.0. First, a descriptive analysis of the parameters (mean and standard error) according to the experimental conditions and evaluation of normality by the Kolmogorov–Smirnov (K–S) test were performed. As all data were considered nonparametric, a Mann–Whitney test was used. The percentages were analyzed by the Fisher’s test. Statistical significance was considered when P < .05.

3. Results

The interval between application of prostaglandin F₂a (PGF₂a) and beginning of treatment was 3.6 (±0.4) and 4 (±0.2) days for the DES and DES + SULP groups, respectively. The mean number of follicles between 20 and 25 mm at the beginning of treatment was similar between groups. The diameter of the largest follicle and second largest follicle at the beginning of treatment did not differ between groups (P > .05). The mean duration of treatment for induction of ovulation was 3.3 (±0.2) and 4 (±0.3) days for the DES and DES + SULP groups, respectively (Table 1). The number of mares that developed at least two follicles ≥33 mm did not differ between groups (DES—90%; DES + SULP—70%), as well as the mean number of follicles ≥33 mm per mare at the time of ovulation induction (DES—2.2; DES + SULP—1.9) (P > .05). The diameter of the largest follicle (DES—36.7; DES + SULP—35.9) at the time of induction did not differ between groups, but a difference in the diameter of the second largest follicle (DES—35.1; DES + SULP—33.1) at the same time (P < .05) was observed (Table 1). The mean number of ovulations did not differ between groups, considering 1.8 and 1.5 ovulations for the DES and DES + SULP groups, respectively. Most of the mares ovulated in synchrony up to 24 hours, with 71.4% (5/7) for the DES group and 80% (4/5) for the DES + SULP group. Asynchronous ovulations were observed in two mares (28.5%) in the DES group and one mare (20%) in the DES + SULP group. The number of mares that ovulated two follicles did not differ between groups (DES—70%; DES + SULP—50%). When we evaluated the number of ovulations corresponding with number of follicles developed above 33 mm in diameter, 18/22 (81.8%) in DES group and 15/19 (79%) in DES + SULP group were observed with no difference between them (P > .05). The interval between the application of PGF₂a and the next ovulation did not differ between groups (Table 1).

In the first cycle, before start the experiment, and the last cycle after finished the experiment, all mares presented normal follicular development (9 ± 1.6 days between PGF₂a application and ovulations) and ovulation (one ovulation per cycle).

4. Discussion

Studies on the induction of double ovulation in mares using deslorelin acetate have recently been described with satisfactory results [7,9–11,17]. Because it is a gonadotropin-releasing hormone (GnRH) analog, deslorelin acetate stimulates the secretion of gonadotrophins by the pituitary gland fostering follicular growth [18].
In addition to being a synthetic hormone and not presenting variation between the departures, deslorelin acetate has low cost and high commercial availability [7].

The treatment period with deslorelin in the present experiment was approximately 4 days, sufficient time for the follicles to reach adequate diameter for the ovulation induction. Irvine [19] described that prolonged treatment with GnRH in several species may induce pituitary desensitization, causing a decrease in gonadotrophin secretion and consequently a decrease in ovarian activity, a phenomenon known as downregulation. This phenomenon could also be observed in a study by Nagao et al [7]. In the present study, no downregulation was observed in any of the treated animals. One of the mares of the DES + SULP group did not show follicular growth after 3 days of treatment, and it was immediately stopped.

A dopamine antagonist drug, sulpiride, has been linked to increased serum prolactin levels, which in turn regulate the receptor population for FSH and LH in the ovaries [12]. Considering the lower condition of the second largest follicle to reach dominance, due to its lower expression of FSH and LH receptors, as observed by Bergfelt and Adams [15], it was decided to associate sulpiride with deslorelin treatment in an attempt to elevate the receptor population for FSH and LH in the codominant follicle, thus enabling its growth until ovulation. A recent study in the attempt to stimulate multiple ovulations in cyclic mares using sulpiride close to the follicular dominance demonstrated the efficacy of the treatment stimulating ovarian activity but did not contribute to a significant increase in rates of multiple ovulations [20]. When administered orally in horses, the absorption of sulpiride is considered relatively low, around 20% [21]. Taking this fact into account, the dose chosen was higher (about 2.5 mg/Kg) than used in other studies where it was possible to verify serum prolactin elevation following administration of sulpiride IM in mares in the transition phase [13,22]. In addition, it was reported the efficacy of sulpiride in elevating serum prolactin levels after administration of 2 mg/kg orally, in postpartum mares [23] and at 1.5 mg/kg IM in mares in the periovulatory period [24].

Considering rates of follicular development and ovulation, the results observed in the present study were similar to those obtained in recent studies where deslorelin was used to induce double ovulations in mares [7–11]. When evaluating the rate of double ovulation, 70% (7/10) of the mares obtained at least two ovulations when treated with deslorelin because one of them ovulated three follicles. This result was similar to those reported in other studies where deslorelin was used, ranging from 70% (7/10) [9], 79% (39/43) [8], 82% (46/56) [7], and 86.6% [10]. Superior results were described in another experiment, where all mares ovulated two follicles (10/10) [17]. Already in a study conducted by Lima et al. [25], only 25% (3/12) of the mares responded with double ovulation.

The association of sulpiride and deslorelin for double ovulation induction was proposed with the intention to increase the percentage of mares that respond to the treatment with deslorelin, a fact that could not be observed, because in the group where the sulpiride was added to the treatment, only 50% (5/10) of the animals ovulated at least two follicles.

The mean diameter of the second largest follicle in the mares of the DES + SULP group was lower compared to mares receiving deslorelin only ($P < .05$). In a study conducted by Campos et al. [17] in which follicles from 33 mm were submitted to ovulation induction with 1500 IU of hCG, 100% (10/10) of the mares presented double ovulation. Similarly, Nagao et al [7] and Carmono et al [8] obtained satisfactory rates of double ovulation when induction was performed on follicles ≥33 mm with 2,500 IU of hCG. Although these authors report efficacy in ovulation induction of follicles from 33 mm in diameter, others recommend that the ovulation induction hCG be performed from the observation of follicles ≥35 mm [11,26,27]. Thus, waiting one more day to ovulation induction in the DES + SULP mares, at which point the second largest follicle would probably reach a diameter of ≥35 mm, could have increased the number of mares with double ovulation in this group.

Most of the ovulation occurred synchronously in both groups, which becomes extremely important when artificial insemination is performed using refrigerated or frozen semen, thus increasing the embryo recovery rates from a single insemination per cycle.

The mean interval between the application of PGF2α and the next ovulation was similar between the treated groups and in the pretreatment and posttreatment control cycles, demonstrating that

### Table 1

Mean data and standard error of the variables between the group treated with deslorelin and the group treated with deslorelin + sulpiride to obtain double ovulations.

<table>
<thead>
<tr>
<th>Variables</th>
<th>DES</th>
<th>DES + SULP</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of cycles used</td>
<td>10</td>
<td>10</td>
</tr>
<tr>
<td>Time after application of PGF2α and initiation of treatment (d)</td>
<td>3.6 ± 0.4</td>
<td>3.2 ± 0.2</td>
</tr>
<tr>
<td>Number of follicles ≥ 20 mm at initiation of treatment</td>
<td>28</td>
<td>29</td>
</tr>
<tr>
<td>Number of follicles ≥ 20 mm at initiation of treatment per mare</td>
<td>2.8 ± 0.2</td>
<td>2.9 ± 0.3</td>
</tr>
<tr>
<td>Diameter of the largest follicle at initiation of treatment (mm)</td>
<td>24.1 ± 0.3</td>
<td>23.8 ± 0.3</td>
</tr>
<tr>
<td>Diameter of the second largest follicle at initiation of treatment (mm)</td>
<td>22.4 ± 0.4</td>
<td>22.5 ± 0.2</td>
</tr>
<tr>
<td>Days of treatment until ovulation induction</td>
<td>3.3 ± 0.2</td>
<td>4.0 ± 0.3</td>
</tr>
<tr>
<td>Diameter of the largest follicle at ovulation induction (mm)</td>
<td>36.7 ± 0.6</td>
<td>35.9 ± 0.2</td>
</tr>
<tr>
<td>Diameter of the second largest follicle at ovulation induction (mm)</td>
<td>35.1 ± 0.6</td>
<td>33.1 ± 0.1</td>
</tr>
<tr>
<td>Number (%) of mares with at least two follicles ≥ 33 mm at ovulation induction</td>
<td>90% (9/10)</td>
<td>70% (7/10)</td>
</tr>
<tr>
<td>Number (%) of mares with no follicle development ≥ 33 mm 3 d after starts treatment</td>
<td>0% (0/0)</td>
<td>10% (1/10)</td>
</tr>
<tr>
<td>Number of follicles ≥ 33 mm at ovulation induction</td>
<td>22</td>
<td>19</td>
</tr>
<tr>
<td>Average number of follicles ≥ 33 mm per mare at ovulation induction</td>
<td>2.2 ± 0.2</td>
<td>1.9 ± 0.3</td>
</tr>
<tr>
<td>Number (%) of mares with at least two ovulations</td>
<td>70% (7/10)</td>
<td>50% (5/10)</td>
</tr>
<tr>
<td>Number (%) of mares with one ovulation</td>
<td>30% (3/10)</td>
<td>40% (4/10)</td>
</tr>
<tr>
<td>Number (%) of mares with synchronous ovulations up to 24 h</td>
<td>71.4% (5/7)</td>
<td>80% (5/6)</td>
</tr>
<tr>
<td>Number (%) of mares with asynchronous ovulations &gt;24 h</td>
<td>28.5% (2/7)</td>
<td>20% (1/5)</td>
</tr>
<tr>
<td>Number of ovulations</td>
<td>18</td>
<td>15</td>
</tr>
<tr>
<td>Average number of ovulations per cycle</td>
<td>1.8 ± 0.2</td>
<td>1.5 ± 0.2</td>
</tr>
<tr>
<td>Number (%) of follicles ≥ 33 mm did not ovulate</td>
<td>18.15% (4/22)</td>
<td>21.5% (4/19)</td>
</tr>
<tr>
<td>Number (%) of follicles ≥ 33 mm did not ovulate</td>
<td>81.8% (18/22)</td>
<td>78.5% (15/19)</td>
</tr>
<tr>
<td>Interval between PGF2α and ovulation (d)</td>
<td>9.6 ± 0.6</td>
<td>8.8 ± 0.5</td>
</tr>
</tbody>
</table>

**Abbreviations:** DES, deslorelin; PGF2α, prostaglandin F2α; SULP, sulpiride.

* $P < .05$. 
ovarian stimulation did not interfere in the interval between luteolysis and ovulation in the posttreatment cycle.

No improvement in ovarian response was observed in the animals treated with the association of deslorelin and sulpiride when compared to the group treated with deslorelin alone. We conclude that the association of sulpiride and deslorelin acetate did not contribute to the increase in double ovulations rates in mares.

References